Abstract
Introduction: Metered cryospray (MCS) is a bronchoscopic treatment that delivers titrated applications of liquid nitrogen to the airways, to enact the controlled ablation and repopulation with a healthier bronchial epithelium, in patients with COPD with chronic bronchitis.
Aims and objectives: To investigate the effect of MCS on quality of life, in patients with COPD, with chronic bronchitis.
Methods: Patient-reported outcome measures (PROM) were collected from 31 subjects at baseline and at 6-months post-procedure, in a sham-controlled, blinded, 1:1 randomised trial.
Results: A clinically meaningful and statistically significant change in St George's respiratory questionnaire (SGRQ) total score was observed between arms, at 6-months post-MCS treatment (-9.6 points; p=0.02), compared to baseline.
Change in PROM scores at 6-months post-procedure, compared to baseline. *Paired t-test for change in the MCS arm, relative to baseline. †Two samples t-test for the between arms difference, in change relative to baseline. SGRQ: St George’s respiratory questionnaire; CAT: COPD assessment test
Conclusions: The change in patient-reported outcome measures at 6-months post-MCS, relative to baseline, confirms that MCS is efficacious in improving quality of life in patients with COPD, with chronic bronchitis.
Footnotes
Cite this article as Eur Respir J 2022; 60: Suppl. 66, 4679.
This article was presented at the 2022 ERS International Congress, in session “-”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022
